65 results about "Pneumonocyte" patented technology

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The invention discloses a compound derivative represented by a formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt thereof. According to the application of a double protection strategy, diversified carrier fragments are introduced to 5-hydroxyl and hydroxylamine in N4-hydroxycytidine molecules, the N4-hydroxycytidine prodrug is invented, the affinity of lung cell membranes (phospholipid membranes) is improved, and the physicochemical properties of the drug are made to meet the requirements of the physiological environment of lung tissue. Therefore, the compound disclosed by the invention has a wide application prospect in the aspect of broad-spectrum respiratory virus resistance. # imgabs0 #

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention discloses hydrogel bio-ink, a preparation method of the hydrogel bio-ink, a 3D printing biodegradable airway stent and application of the 3D printing biodegradable airway stent. The preparation method comprises the following steps that S1, lung tissue is subjected to freeze thawing, slicing, sequential decellularization of SDS and TritonX-100, air drying, smashing and cryopreservation, and a lung extracellular matrix is obtained; s2, performing sterilization and pepsin treatment on the lung extracellular matrix prepared in S1 to obtain a pretreated lung extracellular matrix; and S3, mixing methyl propionylated gelatin and an alginate solution, pouring the mixture into solid gel, gelatinizing the solid gel, and adding the pretreated lung extracellular matrix to prepare the hydrogel bio-ink. The prepared pig lung acellular extracellular matrix does not have an obvious nuclear structure, and DNA (Deoxyribonucleic Acid) determination shows that the concentration of an acellular group is obviously reduced (P is less than 0.01); along with the increase of the dECM concentration, the porosity is reduced, and the degradation time is prolonged; the airway stent is printed in a 3D biological printing mode, no obvious cytotoxicity (P is larger than 0.05) exists in a cytotoxicity experiment, and the mechanical property part of the airway stent is similar to that of a silicone stent.

The present invention relates to a compound of Formula 1, a preparation method thereof, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The compound of Formula 1 according to the present invention can exhibit cell necrosis and ferroptosis inhibitory efficacy in various cells such as heart, kidney, nerve, retina, liver, or lung cells, and accordingly, can be usefully used for prevention or treatment of cell necrosis or ferroptosis-related diseases

The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

The invention discloses a construction method and application of a human lung 3D cell microsphere and a human pulmonary fibrosis 3D organoid. The construction of the human lung 3D cell microspheres comprises the following steps: respectively digesting human primary fibrosis cells and human II-type alveolar epithelial cells which are subjected to adherent culture into single cells; mixing digested human primary fibrotic cells, human II-type alveolar epithelial cells and THP-1 macrophages subjected to suspension culture according to a cell number ratio of 1: 1: 1, so as to obtain a cell precipitate; and preparing the cell precipitate into cell matrigel microspheres by using a T-type microfluidic technology, and culturing to obtain the human lung 3D cell microspheres. And further inducing the human lung 3D cell microspheres by using a human lung organoid culture medium containing 50ng / mL of TGF-beta for 24-48 hours to obtain the human pulmonary fibrosis 3D organoid. According to the invention, 3D cell microspheres with human normal lung cell characteristics and protein expression can be formed within 3 days, and pulmonary fibrosis 3D organs can be obtained after short-time induction.

The invention belongs to the technical field of biological medicines, and particularly relates to application of MIM2 and derivatives thereof in preparation of products for treating tissue fibrosis. It is found that the compound MIM2 can effectively inhibit expression and synthesis of various cancers (extracellular matrix proteins such as collagen and laminin in cells). In-vitro experiments show that after MIM2 treatment, collagen and laminin expression of the cancer cells, skin fibroblasts, hepatic stellate cells and embryonic lung cells is remarkably reduced. Animal experiments further prove that the MIM2 can effectively inhibit collagen deposition in tumor tissues of tumor-bearing mice, can slow down the fibrosis process of liver fibrosis and pulmonary fibrosis mouse models, and can reduce the level of plasma hyaluronic acid at the same time. The results show that the MIM2 has the effects of inhibiting extracellular matrix deposition and delaying tissue fibrosis, and is expected to be developed into small molecular drugs for treating cancer-related fibrosis and other fibrosis diseases.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present invention provides processes for producing a bioengineered lung (BEL) from an acellular lung matrix that has been treated with growth hormones, seeded with primary lung cells, and cultured in a bioreactor. Also provided are BELs and methods of transplanting the BEL into a subject in need of a lung transplant, and methods for using BELs for the study of the lung microbiome and its role in lung development and remodeling.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (RM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker 5 expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

The application belongs to the technical field of biological medicine, and particularly relates to the use of a lung extracellular matrix hydrogel in the preparation of a lung injury repair material. The application grafts methacrylic anhydride groups on a lung tissue-derived extracellular matrix, and provides a lung extracellular matrix hydrogel which can be rapidly photo-crosslinked, has high stability, effectively promotes angiogenesis, and prevents postoperative leakage. The photo-crosslinked lung extracellular matrix hydrogel of the application is applied to a lung injury animal model, significantly promotes angiogenesis, promotes alveolar regeneration, and also significantly reduces the fibrosis level. Compared with a sealing agent alpha-cyanopropyl acrylate gel and a fibrin glue which are used in clinical application, the photo-crosslinked lung extracellular matrix hydrogel has excellent effects on repairing lung injury, provides a new strategy for repairing traumatic and iatrogenic lung injury, and has a good application prospect.

The invention provides application of a mitochondrial uncoupling agent BAM15 in preparation of a medicine for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), and the BAM15 can improve lung injury of an organism by maintaining dynamic balance of mitochondria, reducing neutrophil apoptosis delay, relieving oxidative stress and autophagy response and inhibiting a cGAS-STING signal channel. The mitochondrial uncoupling agent BAM15 is used for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), has the advantages of lower cytotoxicity, no interference on plasma membrane potential, wider treatment window and higher safety, and also has the advantages of delayed administration effectiveness, high treatment efficiency and the like, so that the mitochondrial uncoupling agent BAM15 can be applied to treatment of acute lung injury / acute respiratory distress syndrome (ALI / ARDS). The compound is a promising candidate drug for treating acute lung injury / acute respiratory distress syndrome (ALI / ARDS), and is beneficial to relieving mitochondrial injury, maintaining lung cell functions and reducing inflammatory response related to ALI / ARDS.

To provide adeno-associated variants, formulations and methods for pulmonary delivery.SOLUTION: The present disclosure provides variant AAV capsid proteins that confer tropism for lung cells, as well as recombinant adeno-associated viruses comprising the variant AAVs and pharmaceutical compositions comprising the same, and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of lung disorders. (ii) nucleic acids comprising, from 5 ' to 3 ', (a) AAV2 terminal repeats, (b) a promoter, (c) a nucleotide sequence encoding a human cystic fibrosis transmembrane conductance regulator (CFTR) or a biologically active truncated CFTR lacking amino acids 708 to 759 of the human CFTR sequence, (d) a poly-adenylation sequence, and (e) AAV2 terminal repeats.SELECTED DRAWING: None

Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.

RNAi reagents, compositions comprising RNAi reagents, and methods for inhibiting the genome of influenza A virus are described. The influenza A virus (IAV) RNAi reagents and RNAi reagent conjugates disclosed herein inhibit expression of an influenza A virus genome at a targeting portion that spans a variety of known influenza A virus genome variants that are conserved genomes, and thus are capable of inhibiting expression of a variety of influenza A virus strains. Also described are pharmaceutical compositions comprising one or more IAV RNAi agents, optionally in conjunction with one or more additional therapeutic agents. Delivery of the IAV RNAi agents to lung cells in vivo provides inhibition of influenza A virus genomic expression, which can provide therapeutic benefits to subjects, including human subjects, for the treatment of various diseases, disorders and / or symptoms caused by influenza A virus infection.

Disclosed in the present invention are a compound derivative represented by formula I or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomer thereof, or a pharmaceutically acceptable salt thereof. On the basis of the application of a dual-protection strategy, diverse carrier fragments are introduced at the 5-hydroxyl group and hydroxylamine group of the N4-hydroxycytidine molecule to develop an N4-hydroxycytidine prodrug. Such a modification enhances the affinity for a pulmonary cell membrane (phospholipid membrane), rendering the physicochemical properties of the drug suitable for the physiological environment of lung tissue. Therefore, the compound of the present invention has a broad application prospect in the aspect of broad-spectrum anti-respiratory viruses.

The present invention relates to a mouse model of CT45 gene knock-in and its construction method and application, belonging to the field of bioengineering technology. The present invention constructs a CT45 gene knock-in vector and injects it into a mouse to obtain an F0 mouse; the F0 mouse is hybridized with a Cre-LoxP mouse to obtain a CT45 gene expression mouse; finally, the CT45 gene expression mouse is hybridized with a Sftpc-Cre mouse to obtain a gene knock-in mouse that specifically expresses the CT45 gene in the lung, and a CT45 gene knock-in mouse model is successfully constructed. According to genotype identification and experimental verification, the knock-in and specific expression of the CT45 gene cause spontaneous lesions in the mouse lungs, and lung cells become cancerous, which can cause the occurrence of mouse lung cancer in 3-6 months, so the CT45 gene knock-in mouse is a brand-new lung cancer model animal, which can be applied to the preparation of lung cancer diagnosis products and therapeutic drugs, and the screening and development of new anticancer drugs.

The present disclosure provides a system for growing and modeling lung cells in organoid culture, and the method of using it.This document discloses the chemically defined conditions for lung stem cell proliferation, maintenance and differentiation in ex vivo organoid culture.These defined culture conditions provide the means for studying cell type specific effects and for high-throughput pharmacogenomics research to discover drugs for treating disease.

The invention relates to the technical field of tuberculosis vaccines, in particular to a tuberculosis VLP nanoparticle vaccine and preparation and application thereof. According to the tuberculosis VLP nanoparticle vaccine, through up-regulation of Th1 type, Th2 type and TH17 type cellular immune response and down-regulation of Treg cellular immune response, the H37Rv growth inhibition ability of splenic lymphocytes and lung cells in vitro is enhanced, and the cellular immune response induced by EPPE + mi3 / AS01E and the H37Rv growth inhibition ability of the cells in vitro are higher than those of BCG and a corresponding subunit vaccine EPPE / AS01E; in addition, the EPPE + mi3 / AS01E can be used as a BCG booster vaccine, and the cell immune response after BCG immunization and the H37Rv growth inhibition capacity of cells in vitro are improved.

Provided are plasmids comprising transcriptional control elements, including transcription factor binding motifs, telomeric repeat motifs, transcription factor repressor binding motifs and promoters for tunable protein expression in target cells; wherein the plasmid for controlled transcription in a target cell type comprises a transcription factor binding motif for NFIA and the cell expresses NFIA. In one embodiment, the cell type is lung cells and the transcription factor is Nuclear Factor IA (NFIA).

The present application relates to a lactobacillus reuteri HC1602, a bacterial agent and application thereof, and belongs to the technical field of microorganisms. Limosilactobacillus reuteri The lactobacillus reuteri (HC1602) is preserved in the China General Microbiological Culture Collection Center, with a preservation number of CGMCC No. 26890, a preservation date of March 23, 2023, and an address of the preservation agency of No. 3, Beichen West Road, Chaoyang District, Beijing. The present application also provides an application of the lactobacillus reuteri HC1602 in preparing a product for inhibiting and preventing respiratory syncytial virus and an application in preparing a product for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the present application can effectively inhibit the invasion of RSV on A549 lung cells and improve the survival rate of A549 cells.

Provided herein are lung forming progenitor cell therapies which do not require pre-conditioning treatments. Administration of the progenitor cells can replace or replenish populations of host-derived patch forming cells to reverse or inhibit fibrosis, promote healing, and improve lung function. Further disclosed herein are methods for monitoring fibrosis, and for determining whether a subject will be receptive to progenitor cell treatments.

The invention discloses an application of an abrus cantoniensis hance extract in preparation of a medicine for preventing and treating lung injury caused by cigarette smog, the abrus cantoniensis hance extract comprises total saponins, polysaccharides, total flavonoids and total alkaloids, and the survival rate of lung cells injured by cigarette smog induction can be increased; the composition can improve the levels of SOD, GSH, GSH-Px and CAT in normal or injured human bronchial epithelial cells (HBE) and reduce the level of IL-6 in the normal HBE, has a lung injury protection effect, and has important significance in prevention and treatment of respiratory system chronic diseases caused by smoke.

Provided herein are lipid nanoparticle (LNP) compositions for use in delivering a payload to a lung cell of a subject. Also provided are a method for treating and / or preventing a lung disease, kits, pharmaceutical compositions, and other compositions and methods.

The present invention relates to the application of METTL3 in the preparation of drugs for preventing and treating radiation-induced lung injury. The present invention discovers that METTL3 knockdown has a preventive and therapeutic effect on radiation injury of human lung cells and lung tissues in animal models, can inhibit the epithelial-mesenchymal transition process during the occurrence and development of radiation-induced lung injury, and enhance the antioxidant and post-radiation cell proliferation abilities of lung cells. Therefore, the preventive and therapeutic drugs of the present invention are designed with METTL3 as the target gene, and have important significance and application value in dealing with nuclear and radiation accidents, nuclear emergencies, and reducing the lung radiation injury of tumor radiotherapy patients, etc.

The invention relates to the technical field of radiation protection, in particular to a dietary nutrition supplement capable of relieving radon internal irradiation damage and having a protective effect and a preparation method thereof, and the dietary nutrition supplement comprises the following raw materials: compound vitamins, nicotinamide, selenium-enriched yeast and propolis. Animal experiments prove that after the dietary nutrition supplement is taken, the dietary nutrition supplement not only is beneficial to relieving oxidative damage and apoptosis resistance caused by radon irradiation, inhibiting autophagy and relieving damage of radon daughters to lung cells, but also does not generate toxic and side effects, and achieves the purposes of safety and effectiveness.

The utility model provides a suspension cell culture and drug concentration generation integrated micro-fluidic chip, which structurally comprises culture units which are stacked in series, a liquid inlet and a liquid outlet which are mutually independent, each unit comprises a matrix, each culture layer is provided with an independent culture channel, and the micro-channel is modified by bovine serum albumin molecules. A closed loop is formed by vertical overlapping, and cell implantation is realized by a laminar flow phenomenon. And meanwhile, two driving channels are crossed with the culture channel and are separated from the culture channel by an elastic diaphragm. Two ends of the driving channel are communicated with the outside. The liquid inlet and the liquid outlet which are independent from each other automatically form a medicament with a gradient medicament concentration from the sample liquid inlet, the influence of the change of the concentration of the medicament on blood cell culture is researched, the chip suspension culture simulates the real environment of lung cells in vivo, and the bovine serum albumin molecule modification simplifies the cell implantation process. Medicaments with different concentrations are added into different channels, and the optimal concentration range is determined by observing the influence of the medicaments. The method has the advantages of high efficiency and economy.

The present disclosure provides variant AAV capsid proteins that confer tropism to lung cells, and recombinant adeno-associated viruses comprising the variant AAV capsid proteins, and pharmaceutical compositions comprising the same, and their use in delivering heterologous nucleic acids to lung cells for the treatment of lung conditions.